The stock of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) hit a new 52-week high and has $6.33 target or 109.00% above today’s $3.03 share price. The 6 months bullish chart indicates low risk for the $71.11M company. The 1-year high was reported on Oct, 12 by Barchart.com. If the $6.33 price target is reached, the company will be worth $77.51M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 1.53 million shares traded hands or 177.13% up from the average. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) has risen 32.24% since March 9, 2016 and is uptrending. It has outperformed by 24.83% the S&P500.
Analysts await IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) to report earnings on October, 14. They expect $-0.07 earnings per share, up 12.50% or $0.01 from last year’s $-0.08 per share. After $-0.08 actual earnings per share reported by IntelliPharmaCeutics Intl Inc (USA) for the previous quarter, Wall Street now forecasts -12.50% EPS growth.
According to Zacks Investment Research, “Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada.”
Another recent and important IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) news was published by Benzinga.com which published an article titled: “16 Stocks Moving In Monday’s Pre-Market Session” on October 10, 2016.
IPCI Company Profile
Intellipharmaceutics International Inc., incorporated on October 22, 2009, is a pharmaceutical firm specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, the Company has developed several drug delivery systems and a pipeline of products and product candidates at various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.